In Brief
Insights into the architecture and function of bacterial contact-dependent inhibition systems reveal a stalled, partially secreted state that ensures toxin export only upon target cell engagement.
INTRODUCTION
Bacteria have long been known to release diffusible antibiotics and bacteriocins that inhibit competitor cells. Recent research has revealed that bacteria also commonly antagonize their neighbors through direct inter-cellular transfer of protein toxins. In Gram-negative bacteria, type I (García-Bayona et al., 2017) , type II (Jamet et al., 2015) , type IV (Souza et al., 2015) , type V (Aoki et al., 2005) , and type VI (Hood et al., 2010; MacIntyre et al., 2010) secretion systems have all been shown to deploy toxic antibacterial effectors. Gram-positive species exploit distinct mechanisms, using cell-wall-associated YD-repeat pro-teins (Koskiniemi et al., 2013) and type VII secretion systems (Cao et al., 2016; Whitney et al., 2017) to deliver toxins into target bacteria. Direct inter-bacterial toxin exchange was first discovered in Escherichia coli isolate EC93, which uses the CdiB-CdiA two-partner secretion (TPS) system to inhibit other E. coli strains in a process called contact-dependent growth inhibition (CDI) (Aoki et al., 2005) . CdiB is an outer-membrane localized Omp85 b-barrel protein that exports and presents the toxic CdiA effector on the cell surface. CdiA is a very large protein ($320 kDa) that is predicted to form a filament extending several hundred Å from the cell surface (Aoki et al., 2005; Kajava et al., 2001) . CdiA recognizes target bacteria through specific binding interactions with a receptor. Upon binding to receptor, CdiA transfers its C-terminal toxin domain (CdiA-CT) into the target cell to inhibit growth (Aoki et al., 2008) . To prevent self-inhibition, E. coli EC93 also produces an immunity protein, CdiI, which specifically neutralizes CdiA-CT toxins delivered from neighboring sibling cells. Thus, E. coli EC93 uses CDI to suppress the growth of non-isogenic E. coli strains, presumably to compete for limited environmental resources.
Since its discovery in E. coli EC93, CDI systems have been identified in many other Gram-negative bacteria and are particularly common in pathogens (Aoki et al., 2010; Zhang et al., 2012; Zhang et al., 2011) . Though CdiA is not known to intoxicate eukaryotic cells, the effectors contribute to virulence by promoting bacterial auto-aggregation and biofilm formation (Neil and Apicella, 2009; Rojas et al., 2002) . CdiA proteins are heterogeneous in sequence and length, ranging from $180 kDa in Moraxella to over 630 kDa in some Pseudomonas species (Willett et al., 2015b) . Despite this diversity, CdiA proteins share the same general domain architecture. The N terminus carries a signal peptide for Sec-dependent secretion into the periplasm and a conserved TPS transport domain for CdiB-mediated export across the outer membrane ( Figure 1A) . The N-terminal half of CdiA is dominated by FHA-1 hemagglutinin peptide repeats (Pfam: PF05594) ( Figure 1A) . These motifs were first identified in the filamentous hemagglutinin (FHA) adhesins produced by Bordetella species (Relman et al., 1989) . Structural modeling and electron microscopy of FHA indicate that FHA-1 repeats form an elongated b-helix, with each $20-residue motif extending the helix $4.8 Å (Kajava et al., 2001; Makhov et al., 1994) . The C-terminal half of CdiA contains a second repeat domain composed of uncharacterized FHA-2 repeats (PF13332) ( Figure 1A) . FHA-2 repeats are predicted to adopt b secondary structure, but these sequences are distinct from FHA-1, and it is unclear whether this domain is filamentous. The receptor-binding domain (RBD) of CdiA resides between the two FHA repeat regions. RBD sequences can differ between otherwise closely related CdiA proteins, enabling the effectors to recognize unique receptors . In E. coli, three RBD classes have been characterized that bind to BamA (Aoki et al., 2008) , heterotrimeric OmpF/OmpC (Beck et al., 2016) , and the Tsx nucleoside transporter ( Figure 1A ). Lastly, growth inhibition activity resides within the CdiA-CT region, which often varies dramatically in sequence between bacteria (Aoki et al., 2010) . E. coli isolates collectively encode at least 18 CdiA-CT sequence types that exhibit distinct toxic activities. For example, CdiA-CT EC93 from E. coli EC93 dissipates the proton gradient in target bacteria (Aoki et al., 2009) , whereas CdiA-CT STECO31 from E. coli STEC_O31 contains an EndoU RNase domain that cleaves tRNA Glu (Michalska et al., 2018) ( Figure 1A ). CdiA-CT regions are typically demarcated by conserved peptide motifs, such as the ELYN sequence in Burkholderia species or VENN in enterobacteria (Willett et al., 2015b) . The latter VENN motif is part of a larger ''pre-toxin'' (PT) domain annotated as the PT-VENN region (PF04829) (Zhang et al., 2011) ( Figure 1A ). The function of the PT domain is unknown, but its location suggests it could mediate auto-proteolysis to release the toxin for transport into target bacteria.
Although CdiA is thought to form a cell-surface filament, its orientation and architecture have yet to be examined experimentally. The original ''toxin-on-a-stick'' model proposed that CdiA extends its C terminus away from the cell to facilitate toxin transfer into target bacteria (Aoki et al., 2011) . This model implies that the FHA-1 and FHA-2 domains form a continuous filament, with the C-terminal toxin near the distal tip. This scenario appears to be incongruent with the recent discovery that the RBD is located between the FHA repeat regions , which would place the RBD in the middle of the filament. The mechanisms governing CdiA-CT delivery are also poorly understood. E. coli CdiA proteins recognize various OMPs as receptors, suggesting that these b-barrel proteins could also be exploited as toxin translocation conduits. However, the E. coli BamA b-barrel is not open to the cell surface (Albrecht et al., 2014) , and the narrow ($3-5 Å ) hydrophobic lumen of Tsx presumably restricts the passage of peptides (Ye and van den Berg, 2004) . Further, some CdiA proteins use lipopolysaccharide as a receptor (Koskiniemi et al., 2015) , suggesting that OMPs are not necessarily required for toxin translocation. CDI toxin transport across the target-cell cytoplasmic membrane is also dependent on specific receptors. The CdiA-CT region is typically composed of two variable domains, with the extreme C-terminal domain constituting the actual toxin (Willett et al., 2015b ) ( Figure 1A ). Genetic evidence suggests that the N-terminal domain of the CdiA-CT hijacks integral membrane proteins to transport the tethered C-terminal toxin into the target-cell cytoplasm (Willett et al., 2015a) . Each N-terminal ''translocation'' domain recognizes a different membrane protein. For example, the PtsG glucose transporter is required for CdiA-CT STECO31 delivery ( Figure 1A ), but CdiA-CT Dd3937 from Dickeya dadantiii 3937 uses the ribose ABC transporter RbsC to enter the cytoplasm (Willett et al., 2015a) . Though the co-opted membrane proteins are commonly metabolite transporters, their solute-transport activities are not required for toxin import.
Here, we uncover several new and unexpected insights into CdiA secretion and toxin delivery. Electron cryotomography (ECT) reveals that individual CdiA proteins form thin, 33-nm long filaments on the cell surface. Remarkably, CdiA export across the outer membrane is arrested during biogenesis, and the extracellular filament corresponds solely to the N-terminal half of the effector. We identify and delineate a previously unrecognized CdiA domain that is required for this secretion arrest. This Tyr/Pro-enriched region ensures that the C-terminal half of CdiA-including its toxin domain-remains sequestered within the periplasm prior to target-cell recognition. CdiA export resumes upon binding receptor, and the FHA-2 region is deposited directly onto the surface of target bacteria. The FHA-2 domain associates stably with the target-cell outer membrane, and this interaction is required for CdiA-CT transport into the periplasm of target bacteria. We propose that FHA-2 forms a membrane-embedded structure for CdiA-CT translocation. This unprecedented mechanism presumably contributes to CdiA modularity, enabling the effectors to deliver diverse cargoes.
RESULTS

CdiA Forms a Filament on the Cell Surface
We used ECT to visualize CdiA EC93 in its native context on the bacterial cell surface. To image effectors in the pre-delivery state, we used E. coli EC93 bamA LT2 cells, which express Ba-mA LT2 from Salmonella typhimurium LT2. The surface epitopes of BamA LT2 differ significantly from E. coli BamA, thus preventing recognition by CdiA EC93 (Ruhe et al., 2015; Ruhe et al., 2013) . Tomography revealed poorly resolved filaments on EC93 cells (Figure S1A and Table S1 ). We reasoned that the surface O-antigen layer of E. coli EC93 could obscure the filaments, and therefore, we produced CdiA in E. coli K-12 strains that lack both O-antigen and CdiA-receptors. CdiA EC93 filaments were readily apparent on the surface of these latter cells (Figures 1B and S1B, Table  S1 , and Video S1), and this approach facilitated further experiments using minicells for higher resolution imaging (Figures 1C and S1C and Video S2) . Similar filaments were also observed on bacteria and minicells that express CdiA STECO31 from E. coli STEC_O31 ( Figure 1D , Table S1 , and Video S3). Notably, we did not detect filaments on control cells that lack cdi expression constructs (Table S1 and Video S4). Analysis of >100 CdiA EC93 filaments revealed considerable heterogeneity. A few filaments were associated with additional periplasmic density ( Figure 1E ), and others projected from the cell surface at an angle ( Figure 1F ). We also observed some bent structures ( Figure S1D ) and instances of twinned and clustered filaments ( Figure S1E ). The average length of CdiA EC93 filaments was 33 ± 4 nm ( Figure 1G ). Though filament width could not be determined at this resolution, it was clearly % 4 nm, consistent with a parallel b-helix.
We previously showed that CdiA EC93 is also produced in a truncated form that lacks the FHA-2, PT, and CdiA-CT domains (Aoki et al., 2005; Ruhe et al., 2015) . Although truncated CdiA EC93 cannot mediate CDI, it retains BamA-specific adhesin activity (Ruhe et al., 2015) , indicating that it is presented on the cell surface. To determine whether truncation affects filament structure, we imaged CdiA EC93 truncated after residues Ser832, Gly1318, Val1929, and Thr2122 ( Figure 1A ). We did not detect surface structures with the two shortest constructs (Table S1 ), but proteins truncated after Val1929 and Thr2122 form filaments with the same dimensions as CdiA EC93 produced from the full-length construct ( Figure 1G ). Thus, the FHA-2, PT, and CdiA-CT domains are not part of the surface structure, indicating that the extracellular filament corresponds to the N-terminal half of CdiA.
CdiA Surface Topology ECT indicates that the C-terminal half of CdiA is either sequestered within the cell or not resolved because it is disordered or flexible. To distinguish between these possibilities, we examined CdiA surface topology using biochemical approaches. CdiA STECO31 was used for these experiments because antisera to its N-and C-terminal regions are available. Immunoblotting showed that CdiA STECO31 is produced in both full-length and truncated forms when expressed in cells that lack its receptor Tsx ( Figure 2A, lanes 1 and 4) . The N-terminal TPS domain can be digested with extracellular proteinase K (Figure 2A , lane 2), (Figure 2A , lane 5). Trypsin generates a similar C-terminal fragment, but the TPS domain is resistant to this protease (Figure 2A , lanes 3 and 6). These results suggest that FHA-2 and CdiA-CT are intracellular, but it is also possible that these domains are simply protease resistant. Therefore, we developed a fluorescent dye-labeling approach to differentiate periplasmic and extracellular residues. We first showed that the outer membrane is impermeable to maleimide-conjugated IRDye 680LT using His 6 -tagged maltose-binding protein (MBP) engineered to carry a single Cys residue. Periplasmic MBP-Cys-His 6 is not labeled when whole cells are treated with dye but becomes labeled when the outer membrane is permeabilized with polymyxin B ( Figure 2B , lanes 1 and 2). The cytoplasmic membrane remains intact during polymyxin treatment because MBP-Cys-His 6 lacking a signal peptide is not labeled under these conditions ( Figure 2B , lanes 2 and 5). Cytoplasmic MBP becomes accessible to dye only when cells are completely disrupted (Figure 2B, lane 6) . Thus, polymyxin selectively permeabilizes the outer membrane and can be used to probe the periplasm.
We then introduced Cys residues along CdiA STECO31 for dyelabeling studies ( Figure 2C ). Each Cys-substituted effector retains growth inhibition activity against target bacteria (Figure S2A) , demonstrating that the mutations do not perturb function. Wild-type CdiA STECO31 contains four Cys residues that do not react with dye ( Figure 2D , lanes 1 and 2), suggesting that they form disulfide bonds. Engineered Cys residues at positions 504, 1,550, and 1,693 label efficiently, with dye fluorescence superimposing with anti-TPS antibody signal ( Figure 2D , lanes 3-8). These Cys residues are extracellular because they are accessible without polymyxin treatment. By contrast, positions 1,726, 2,502, 2,731, and 3,217 of CdiA STECO31 are labeled only when the outer membrane is permeabilized ( Figure 2D ). Position 1,807 is relatively unreactive even with polymyxin treatment ( Figure 2D , lanes 11 and 12), suggesting that its side-chain is occluded. These results indicate that the FHA-2, PT, and CdiA-CT domains reside in the periplasm prior to target-cell recognition. The periplasmic region also contains a small cluster of FHA-1 motifs, which we have termed periplasmic FHA-1 repeats (pFR) ( Figure 2C ). The function of these repeats is unclear, but this region is conserved in other CdiA proteins ( Figure S3 ).
CdiA-Receptor Binding Interactions
The receptor-binding domain (RBD) of CdiA presumably forms the distal end of the filament. To localize the RBD, we incubated CdiA EC93 -expressing minicells with purified E. coli BamA and imaged using ECT. As predicted, BamA-containing micelles bind to the distal tips of the filaments, forming ''lollipop''-like structures (Figures 3A and 3B) . In some instances, filaments bundle together as they interact with larger micelles that presumably contain multiple receptors ( Figures 3A and 3C ). These interactions are BamA-dependent because detergent micelles lacking BamA do not bind CdiA EC93 and instead tend to interact with the cell surface ( Figure 3D ). Remarkably, BamA-bound filaments are significantly elongated, increasing approximately 5 nm to an average length of 38 ± 3.6 nm ( Figure 1G , see STAR Methods for statistical comparisons and p values). We obtained similar results with target minicells that express E. coli BamA and captured an image of two minicells bridged by an individual filament ( Figure 3E ). However, most of the interactions involved vesicles that were presumably derived from the BamAexpressing target cells (Figures 3F and 3G) . Given that the periplasmic space is often widened and distorted in minicells, these vesicles may have been stripped from target cells upon binding to CdiA EC93 . The vesicle-bound filaments were also elongated to 38 ± 4.9 nm ( Figure 1G ). These data indicate that the RBD is at the distal end of the filament, suggesting that the TPS domain is associated with CdiB at the cell surface. Therefore, the CdiA chain must make a hairpin-turn at the RBD and return to the cell for the C-terminal domains to remain in the periplasm. Notably, only 176 residues separate position 1,550 in the RBD from position 1,726 in the periplasm, indicating that some portion of the intervening sequence must be extended (at $3.5 Å per residue) to span the 33-nm filament. This region is enriched for Tyr (Y) and Pro (P) residues relative to the surrounding FHA repeat domains ( Figure S4 ) and is abruptly demarcated from the variable RBD sequence by a conserved YPLP motif (Figure S3 ). This previously unrecognized ''YP domain'' is conserved in other species (Table S2 and Figure S3 ) and is of particular interest because dye-labeling indicates that this region crosses the outer membrane.
CdiA Export Resumes upon Binding Receptor
Filament elongation suggests that CdiA undergoes structural reorganization upon binding receptor. Moreover, effector topology must change dramatically for the C-terminal toxin domain to be transferred into target bacteria. Therefore, we used the dyelabeling approach to monitor topological changes in response to the addition of target bacteria. Immunoblotting revealed that the CdiA-CT region of CdiA STECO31 is cleaved upon mixing with tsx + target cells, but not with Dtsx mock targets ( Figure 4A , lanes 1 and 2). Thus, this CdiA-CT processing is indicative of toxin delivery. The reactivity of extracellular positions 504 and 1,693 is unaltered by target bacteria, but labeling at position 1,550 is diminished in the presence of tsx + targets ( Figure 4A , lanes 5 and 6). Because residue 1,550 lies within the RBD, it may become occluded through direct interaction with Tsx. Strikingly, positions 1,726, 1,807, 1,959, and 2,502 all become accessible to extracellular dye when tsx + cells are introduced but remain periplasmic with mock Dtsx targets ( Figure 4A ). These data suggest that the C-terminal region is exported upon binding Tsx, but it is also possible that outer membranes become permeable to dye in response to CdiA-receptor binding. This is not the case, however, as MBP-Cys-His 6 in the inhibitor-cell periplasm remains unreactive when tsx + targets are introduced ( Figure 4B , lanes 3 and 4). In contrast to other Cys substitutions, residue 2,731 in the PT domain remains unlabeled with tsx + targets (Figure 4A , lanes 17 and 18), suggesting that it may be transferred into the target cell. We note that position 3,217 cannot be detected because it lies within the cleaved CdiA-CT region. To monitor this latter position, we blocked CdiA-CT processing by mutating the VDNN motif to VDNA ( Figure 4C , lanes 1 and 2) and repeated the topology mapping with a subset of Cys substitutions. The VDNA mutation has no effect on Cys reactivity at positions 504, 1,550, and 2,502 ( Figure 4C , lanes 3-8). Positions 2,731 and 3,217 show some labeling in the presence of tsx + targets but at lower efficiencies than position 2,502 ( Figure 4C , compare lanes 8, 10, and 12). Residues 2,731 and 3,217 appear to be transferred into the periplasm of target cells because they are labeled more efficiently when the mixed cell suspensions are permeabilized with polymyxin ( Figure 4D , lanes 10 and 12). Together, these data indicate that CdiA export resumes upon binding receptor, with the PT and CdiA-CT domains being transferred into target bacteria. Because N-terminal residues remain extracellular, the CdiA chain must pass through the outer membrane of the target cell.
The YP Domain Is Required for Cell-Surface Presentation We next disrupted the FHA-1, RBD, YP, FHA-2, and PT domains with 100-residue in-frame deletions to examine their functions during CDI ( Figure 5A ). The YP domain was dissected further with 50-residue deletions to test its extracellular region (DYP-N) and membrane-spanning segment (DYP-C). We also removed a portion of the periplasmic FHA-1 repeat (DpFR) region to probe its function. Though the DFHA-1 effector retains nearly wild-type inhibition activity, the other deletion constructs fail to inhibit target cells in shaking-broth co-cultures (Figure S2B ). Receptor-binding function was then assessed by flow cytometry to monitor cell-cell adhesion. GFP-labeled inhibitor cells were mixed with DsRed-labeled target cells, and the mixtures were analyzed by flow cytometry to quantify aggregates with dual green and red fluorescence. Cells expressing wild-type CdiA STECO31 bind $80% of tsx + target cells ( Figure 5B ). Adhesion is CDI-dependent because Dtsx cells are bound at much lower levels, and mock inhibitors lacking CdiA STECO31 do not bind tsx + targets ( Figure 5B ). As expected, the DRBD deletion abrogates target-cell binding, but effectors carrying YP domain deletions are also defective for adhesion ( Figure 5B ). The remaining effectors retain nearly wild-type cell-adhesion activity ( Figure 5B ). Immunoblotting showed low levels of DYP-C and DYP-100 relative to the other effectors, and these proteins were released into the culture supernatants ( Figure S5A , lanes 5 and 6). This latter finding suggests that their defects in cell-cell adhesion are due to an unstable association with the inhibitor-cell surface. This phenomenon could also interfere with growth inhibition activity, particularly in shaking broth cocultures. Therefore, we re-examined deletion construct activity on solid media, where inhibitor and target cells are held in close proximity within a structured environment. Strikingly, the YP deletion constructs inhibited target bacteria on solid media, with the DYP-100 effector exhibiting nearly wild-type growth-inhibition activity ( Figure 5C ). Further, this activity is tsx-dependent ( Figure 5C ), demonstrating that the DYP-100 deletion does not disrupt the adjacent RBD. Thus, the YP domain is not necessary for toxin delivery but is critical when cell-cell interactions are transient. Collectively, these results show that the membrane-spanning segment of the YP domain is required for stable presentation on the inhibitor-cell surface. The FHA-2 Domain Is Required for Toxin Delivery To determine which steps in the CDI pathway are disrupted by the various deletions, we examined how each effector responds to target bacteria. Immunoblotting showed that Tsx-dependent CdiA-CT processing is defective for each effector except the DFHA-1 protein (Figure 5D, lanes 3 and 4) . Notably, the DpFR and DFHA-2 proteins are cleaved at novel sites when mixed with tsx + cells, but not mock targets ( Figure 5D , white carets in lanes 14 and 16), suggesting aberrant processing during toxin delivery. We screened protease-deficient E. coli strains and found that OmpT is required for this activity. OmpT protease is embedded in the outer membrane with its active site facing the extracellular milieu Vandeputte-Rutten et al., 2001) . In principle, OmpT on either the inhibitor or target cell could catalyze cleavage, but CdiA degradation depends solely on OmpT in the target cell ( Figure 5E, lanes 2, 4, 6, and 8) . Further, OmpT-mediated cleavage releases C-terminal CdiA fragments into the culture supernatant ( Figure S5B, lanes 10 and 12) . The masses of the OmpT-dependent fragments indicate that the DpFR and DFHA-2 chains are each cleaved near their respective deletion sites, suggesting that the entire FHA-2 region is brought into close proximity with the target-cell surface. However, OmpTmediated proteolysis does not explain the defects in inhibition activity because tsx + DompT target cells are not inhibited by the DpFR and DFHA-2 effectors even when co-cultured on solid media ( Figure 5C ). Moreover, the CdiA-CT toxin region is not processed when DpFR and DFHA-2 effectors bind to tsx + DompT target cells ( Figure 5E, lanes 3, 5, 7, and 9) . Therefore, the pFR and FHA-2 regions are critical for CdiA-CT delivery into the target-cell periplasm.
We introduced Cys substitutions into the DRBD, DYP-N, DpFR, DFHA-2, and DPT effectors ( Figure 6A ) and monitored surface topology after addition of tsx + DompT target cells. As expected, Cys residues in the DRBD protein show no changes in reactivity when target cells are introduced ( Figure 6B) . Similarly, the DYP-N protein shows only modest labeling of periplasmic residues 2,502, 2,731, and 3,217 when mixed with targets (Fig-ure 6C) . In contrast, all periplasmic positions become accessible to extracellular dye when the DpFR and DFHA-2 effectors bind to target bacteria ( Figures 6D and 6E) , indicating that Tsx-interactions trigger export, but the PT and CdiA-CT domains are not transferred into target bacteria. Disruption of the PT domain Figure 6F, lane 12) . However, labeling at position 2,731 is suppressed in the DPT effector, similar to what is observed when this residue is probed in the context of full-length CdiA STECO31 (compare Figure 6F , lane 10 with Figure 4A, lane  18) . This latter observation suggests that residue 2,731, which is N-terminal to the DPT deletion, is still transferred into the target-cell periplasm. Therefore, the pFR, FHA-2 and PT disrup-tions have no effect on receptor-triggered export but prevent CdiA-CT delivery into target bacteria.
The DpFR and DFHA-2 deletions both prevent CdiA-CT transfer into the target-cell periplasm, and these effectors are susceptible to OmpT-mediated cleavage at the target-cell surface. These observations raise the possibility that FHA-2 integrates into the target-cell outer membrane to form a translocon for toxin delivery. To explore this hypothesis, we incubated tsx + target cells with inhibitors that express Cys1959-substituted CdiA STECO31 , then incubated the suspension with maleimide-dye and proteinase K. Analysis of CdiA from this experiment revealed a large (>130 kDa) dye-labeled fragment that is resistant to proteolysis ( Figure 6G, lane 4) . Dye labeling demonstrates that this fragment is derived from CdiA that was exported in response to target bacteria ( Figure 6G, compare lanes 2 and 4) . The dyelabeled fragment also reacts with PT/CdiA-CT antisera, indicating that it encompasses the entire FHA-2 region. Finally, we found that this fragment migrates in the outer-membrane fraction on sucrose gradients ( Figure 6G ), consistent with a stable interaction between FHA-2 and target-cell outer membranes. By contrast, a protease-resistant fragment was not detected with DFHA-2 effectors carrying the Cys1959 substitution (Figure 6H, lane 4) . These results strongly suggest that an intact FHA-2 region is required for stable association with the targetcell outer membrane.
DISCUSSION
Here, we present the first ultrastructural images of CdiA in its near-native state. ECT revealed that each CdiA effector forms a thin filament extending $33 nm from the cell surface. These dimensions are consistent with the b-helix model (Kajava et al., 2001) , which predicts that the FHA-1 region of CdiA EC93 should form a $27 nm filament. The TPS transport domain could account for another $3 nm based on the crystal structures of homologous domains in Bordetella FhaB and Haemophilus HWM1 (Clantin et al., 2004; Yeo et al., 2007) . Given our finding that the RBD forms the filament tip, the TPS domain must be at the other end of the filament, likely associating with CdiB at the cell surface ( Figure 7A ). We also discovered that CdiA is subject to secretion arrest, and the entire C-terminal half of the effector is retained within the periplasm. Therefore, extracellular CdiA must follow a hairpin-like trajectory, first extending outward to form the RBD, then returning back to the cell to enter the periplasm ( Figure 7A ). This topology imposes constraints on the sequence linking the distal RBD to the periplasmic FHA-2 domain. The peptide chain must be extended in this region to span the length of the extracellular filament. Because the YP domain traverses the outer membrane and is required for secretion arrest, we predict that it passes through the central lumen of CdiB to halt export and stabilize CdiA on the cell surface. Further, this export arrest appears to be universal because similar YP domains are found in all recognizable CdiA proteins. Given that FHA-1 varies considerably in size between species (Willett et al., 2015b) , our model predicts that the extended return region should exhibit commensurate changes to accommodate different filament lengths. Indeed, analysis of 142 CdiA proteins from enterobacteria revealed that the size of the variable RBD is directly proportional to FHA-1 length ( Figure 7B & Table S2 ). This correlation is remarkably robust (r 2 = 0.87) for filaments ranging from $14 to 100 nm in predicted length. Therefore, the RBD must contribute significantly to the extended region because the length of the YP domain is essentially invariant (Table S2 ). These observations suggest that the RBD, which is defined as the variable region between the FHA-1 and YP domains, may (3), perhaps forming a b-barrel translocon. Once transferred into the target-cell periplasm, the CdiA-CT region is cleaved (4) for transport into the cytoplasm (5). (B) RBD size is proportional to filament length. RBD residues are plotted as a function of FHA-1 residues. See Figure S3 and Table S2 . (C) Plot of FHA-2 versus FHA-1 residues for the effectors in (B). See Table S2. in fact contain two domains with distinct functions. We hypothesize that the N-terminal portion of the RBD makes direct contact with receptors based on sequence alignments showing limited homology in this region across species ( Figure S3 ). This model predicts that the additional residues found in longer CdiA proteins do not contribute to receptor-binding per se, but are required to span the filament as the chain returns to the inhibitor-cell surface ( Figure 7A ). We also note that FHA-2 does not scale with filament length ( Figure 7C and Table S2 ), demonstrating that size correlation is limited to the RBD and FHA-1. Together, these observations argue that all CdiA proteins adopt the same general surface topology.
Though CdiA undergoes export arrest, it remains poised to deliver toxin upon encountering target bacteria. Presumably, receptor-recognition generates a signal that causes CdiA export to resume. One possible mechanism involves receptor-induced folding of the RBD, which would exert a force on the extended region and release the YP domain from its ''locked'' state within CdiB (Figure 7A, step 2) . This model may also explain why receptor-bound filaments become elongated. Alternatively, the additional length could correspond to the newly exported FHA-2 domain, which we showed makes contact with target bacteria and becomes stably associated with their outer membranes (see Figures 5E and 7G) . Our results indicate that the FHA-2 domain likely passes through the target-cell outer membrane to deliver the CdiA-CT into the periplasm. The structure of FHA-2 is unknown, but the I-TASSER server (Yang et al., 2015) predicts that it could resemble the b-rich RsaA S-layer protein from Caulobacter or the LptD lipopolysaccharide transporter from Shigella. The latter model is appealing because LptD forms a 26-stranded b-barrel in the outer membrane, which would be ideal for toxin translocation. Irrespective of its precise structure, we propose that FHA-2 interaction with the target-cell outer membrane is closely coupled with its export from the inhibitor cell ( Figure 7A, step 3 ). This would allow FHA-2 to integrate as an unfolded chain emerging from the inhibitor cell. This hypothesis could explain why the constitutively released DYP-100 effector is inactive in shaking broth co-culture (see Figure S2B ) but retains nearly wild-type growth inhibition activity on solid media (see Figure 5C ). Following release into the medium, the FHA-2 domain is presumably free to adopt a conformation that precludes membrane integration. However, when released in a crowded sessile community, some of the CdiA will likely be deposited directly onto target bacteria before FHA-2 has the opportunity to fold. Thus, secretion arrest is not strictly required for CDI, but this feature is critical to ensure that the FHA-2 translocon is deployed only when a suitable target membrane is nearby.
The outer-membrane translocation mechanism proposed here is novel and distinct from other inter-bacterial competition systems. Type VI secretion systems rely on mechanical force to deliver toxic payloads. Type VI systems utilize a phage-related contractile apparatus to eject a toxin-laden spear that perforates the outer membranes of neighboring bacteria (Basler et al., 2012; Russell et al., 2014) . This mechanism is sufficient to deliver lytic enzymes that degrade the bacterial cell wall and membrane lipids, but it remains unclear how these systems transfer nuclease toxins into the cytoplasm. Myxobacteria have the unique ability to merge outer membranes, thereby allowing lipids and OMPs to be shared freely between cells (Pathak et al., 2013; Vassallo et al., 2015) . Wall and coworkers have recently shown that polymorphic lipoprotein toxins are also transferred during this process, enabling cells to discriminate kin when engaging in this social behavior (Vassallo et al., 2017) . Because the lipoprotein toxins are tethered to the inner leaflet of the outer membrane, they are able to flow between cells without physical translocation across a lipid bilayer. Toxin translocation has been studied most extensively with colicins. These diffusible protein toxins bind specific surface receptors, then recruit porins as portals for entry into the target-cell periplasm (Cascales et al., 2007; Housden and Kleanthous, 2012) . Transport through the porin is powered by Tol and Ton system proteins, which harness energy from the proton gradient across the bacterial cytoplasmic membrane. Thus, colicins cannot penetrate the outer membrane when bacteria are treated with uncoupling agents that dissipate the proton gradient. Intriguingly, Dtol Dton mutants are completely resistant to colicin-mediated killing, but are fully sensitive to CDI (Ruhe et al., 2014) . Moreover, CdiA-CT toxins are readily delivered into the periplasm of de-energized cells, though the proton gradient is required for subsequent transport into the cytoplasm (Ruhe et al., 2014) . These observations underscore fundamental differences between colicins and CDI, but also raise important unresolved questions about the thermodynamics of CdiA-CT transport across the outer membrane.
Finally, our results could have implications for the function of FHA adhesins in Bordetella. FHA is derived from the FhaB preprotein, which is processed during biogenesis to remove its large C-terminal ''prodomain'' . The domain architecture of FhaB is quite similar to CdiA, and the prodomain contains an FHA-2 repeat region (Aoki et al., 2005; Willett et al., 2015b) . In another parallel, Cotter and coworkers have shown that the FhaB prodomain resides in the periplasm during biogenesis (Noë l et al., 2012) . This phenomenon is thought to promote folding of the exported adhesin domain, after which the prodomain is degraded by periplasmic proteases to release mature FHA from the cell (Noë l et al., 2012; Scheller and Cotter, 2015) . Our work suggests an alternative function for the prodomain. We hypothesize that the FHA-2 repeats in FhaB are used to transport cargo across target-cell membranes. Instead of an antibacterial toxin, the prodomain of FhaB carries an unusual prolyl-rich domain adjacent to the FHA-2 region. The function of this prolyl-rich region is enigmatic, but recent work from the Cotter lab shows that it is important for bacterial persistence in the lower respiratory tract (Melvin et al., 2015) . Collectively, these observations raise the possibility that the prolyl-rich domain is delivered into host cells to modulate immune responses. Thus, Bordetella species may have repurposed the primordial antibacterial CDI mechanism to play a new role in pathogenesis.
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Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial growth conditions Bacterial strains were derivatives of E. coli K-12 strains MG1655 and EPI100. Bacteria were cultured in lysogeny broth (LB) or on LB agar at 37 C. Unless indicated otherwise, media were supplemented with antibiotics at the following concentrations: 150 mg/mL ampicillin (Amp), 100 mg/mL chloramphenicol (Cm), 50 mg/mL kanamycin (Kan), 200 mg/mL spectinomycin (Spc), and 25 mg/mL tetracycline (Tet). 
METHOD DETAILS
Strain constructions E. coli strains are presented in the Key Resources Table. The mreB(A125V) allele (linked to DyhdE::cat) from E. coli DS612 (Shiomi et al., 2013) was transferred into E. coli CH9591 and CH9604 using phage P1-mediated transduction. The DyhdE::cat Cm resistance cassette was subsequently removed using FLP recombinase expressed from pCP20 (Cherepanov and Wackernagel, 1995) to generate strains ZR82 and ZR83 (respectively). ZR82 was transformed with pZR108 (minE overexpression) and CdiA EC93 expressing plasmids to generate minicell producing strains for ECT. The resulting strains were cultured in media supplemented with 0.4% L-arabinose to generate minicells. The Dwzb::kan, Dtsx::kan and DompT::kan disruptions were introduced into E. coli MG1655 from the Keio collection (Baba et al., 2006) by phage P1-mediated transduction. For strains that carry multiple deletions, Kan resistance cassettes were removed with FLP recombinase.
Plasmid constructions
Plasmids are presented in the Key Resources Table and oligonucleotide primers are listed in Table S3 . Cys-substitution mutations Cys substitutions were generated by PCR and the resulting fragments introduced into plasmid pET21b::cdiBAI STECO31 (pCH13604) using restriction endonuclease based cloning. The product from primers ZR260/ZR267 was ligated via NotI/KpnI to generate pZR432 (Ser504Cys). The product from CH403/ZR271 was ligated via SacI to generate pZR433 (Ser1550Cys). PCR fragments from primer pairs ZR268/ZR274 and ZR275/ZR287 were cloned sequentially into pBluescript II SK+ using KpnI/SalI and SalI/NotI, respectively. The KpnI/NcoI fragment was then subcloned to generate pZR434 (Ser1693Cys). PCR fragments from primer pairs ZR268/ZR277 and ZR281/ZR287 were cloned sequentially into pBluescript II SK+ using KpnI/XbaI and XbaI/NotI, respectively. The KpnI/NcoI fragment was then subcloned to generate pZR435 (Gly1726Cys). The product from ZR280/ZR261 was ligated via SexAI/Xho I to generate pZR437 (Ala1807Cys). The product from ZR286/ZR261 was ligated via NcoI/Xho I to generate pZR439 (Asp1959Cys). PCR fragments from primer pairs ZR347/ZR288 and ZR290/ZR261 were cloned sequentially into pBluescript II SK+ using NotI/EcoRI and EcoRI/XhoI, respectively. The NcoI/XhoI fragment was then subcloned to generate pZR441 (Thr2502Cys). PCR fragments from primer pairs ZR347/ZR348 and ZR349/ZR261 were cloned sequentially into pBluescript II SK+ using NotI/BamHI and BamHI/Xho I, respectively. The NcoI/XhoI fragment was then subcloned to generate pZR442 (Ser2731Cys). The product from ZR294/ZR261 was ligated via MfeI/XhoI to generate pZR444 (Ser3217Cys).
In-frame deletion constructs
In-frame deletions within cdiA STECO31 were generated by PCR and introduced into plasmid pCH13604. The fragments from primer pairs ZR268/CH4240 and CH4241/ZR287 were cloned sequentially into pBluescript II SK+ using KpnI/XhoI and XhoI/NotI, respectively. The KpnI/NcoI fragment was then subcloned to generate pCH14028 (DFHA-1: DAsp900-Ala999). The fragments from primer pairs ZR268/CH4243 and CH4244/ZR287 were cloned sequentially into pBluescript II SK+ via KpnI/XhoI and XhoI/NotI, respectively. The KpnI/NcoI fragment was then subcloned to generate pCH14029 (DRBD: DAsn1400-Ser1499). The fragments from primer pairs ZR268/CH4381 and CH4382/ZR287 were cloned sequentially into pBluescript II SK+ via KpnI/XhoI and XhoI/NotI, respectively. The KpnI/NcoI fragment was then subcloned to generate pCH14032 (DYP-100: DPro1658-Asn1757). The fragments from primer pairs ZR268/CH4383 and CH4382/ZR287 were cloned sequentially into pBluescript II SK+ via KpnI/XhoI and XhoI/NotI, respectively. The KpnI/NcoI fragment was then subcloned to generate pCH14030 (DYP-N: DPro1658-Pro1707). The fragments from primer pairs ZR268/CH4383 and CH4384/ZR287 were cloned sequentially into pBluescript II SK+ via KpnI/XhoI and XhoI/NotI, respectively. The KpnI/NcoI fragment was then subcloned to generate pCH14031 (DYP-C: DGly1708-Asn1757). The product from ZR268/CH4245 was ligated via KpnI/NcoI to generate pCH14033 (DpFR: DGly1854-Ser1953). The product from ZR347/CH4247 was ligated via NcoI/AflII to generate pCH14034 (DFHA-2: DThr2324-Gln2423). The fragments from primer pairs CH4371/CH4372 and CH4373/ZR261 were cloned sequentially into pET21b via NheI/SacI and SacI/XhoI, respectively. The AflII/XhoI fragment was then subcloned to generate pCH14035 (DPT: DPro2781-Met2880). The Asn2934Ala mutation in the VDNN motif was generated in three steps. Plasmid pCH13604 was digested with XbaI/SalI, endfilled with T4 DNA polymerase and re-ligated to remove restriction sites upstream of the cdiBAI SdTECO31 gene cluster. An NheI restriction site was introduced into the resulting pCH13658 construct by ligating the PCR product of primers CH4282/CH4283 via AflII/XhoI to generate plasmid pCH13709. Finally, the product from CH4412/CH4374 amplification was used as a template for a second PCR with CH4413/CH4374. The final product was ligated to pCH13709 via NheI/XhoI to generate pCH14036 (VDNA).
Arabinose-inducible constructs for cell-cell adhesion
For cell-cell adhesion assays, the cdiBAI STECO31 gene cluster was overexpressed under an L-arabinose inducible promoter from plasmid pCH13602. Deletion constructs were introduced into pCH13602 through subcloning. The NotI/SacI fragment from pCH14028 was ligated to generate pCH14213 (DFHA-1: DAsp900-Ala999). The NotI/PmlI fragment from pCH14029 ligated to generate pCH14214 (DRBD: DAsn1400-Ser1499). SacI/XcmI fragments from pCH14030, pCH14031 and pCH14032 were ligated to generate plasmids pCH14215 (DYP-N: DPro1658-Pro1707), pCH14216 (DYP-C: DGly1708-Asn1757) and pCH14217 (DYP-100: DPro1658-Asn1757), respectively. NotI/XhoI fragments from pCH14033, pCH14034, pCH14035 and pCH14036 were ligated to generate pCH14218 (DpFR: DGly1854-Ser1953), pCH14219 (DFHA-2: DThr2324-Gln2423), pCH14220 (DPT: DPro2781-Met2880), and pCH14221 (VDNA: Asn2934Ala), respectively.
were used as targets. Targets were also provided with plasmid pCH450 (Dtsx) or pCH13603 (tsx + ). Target cells were grown overnight in LB supplemented with Tet, Amp, 0.4% L-arabinose and 1 mM IPTG to induce expression of Tsx and DsRed prior to mixing with inhibitors. GFP-labeled inhibitor cells were mixed at a 5:1 ratio with DsRed-labeled target bacteria at a final OD 600 $0.2. Cell suspensions were shaken at 30 C for 20 min, diluted into 13 PBS, vortexed briefly, then analyzed on an Accuri C6 flow cytometer using FL1 (533/30nm, GFP) and FL2 (585/40nm, DsRed) fluorophore filters. The fraction of target bacteria bound to inhibitor cells was calculated as the number of dual green/red fluorescent events divided by the total number of red fluorescent events. Three independent experiments were performed on separate days, and > 2,000 red fluorescent events were scored for each cell mixture per experiment.
CdiA domain analyses
CdiA STECO31 homologs were identified by BLAST using residues Asn1637 -Asn1902 as a query to search enterobacterial genera. The query sequence includes the FHA-1 peptide immediately adjacent to the RBD and extends through the periplasmic FHA-1 repeats (pFR). 142 full-length CdiA proteins ranging from 2,963 to 6,442 residues were identified for analysis (Table S2 ). The number of residues comprising each RBD was plotted as a function of the length of the FHA-1 region. The number of residues comprising each FHA-2 domain was determined from automated annotations on the NCBI website (Table S2 ) and plotted as a function of FHA-1 length. The FHA-2 domain of CdiA STECO31 (residues Leu1941 to Met2560) was submitted to the I-TASSER server for protein structure and function predictions (Yang et al., 2015) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters for each experiment are reported in the figure legends and Method Details.
DATA AND SOFTWARE AVAILABILITY
Individual fluorescent channel data for all immunoblots and the I-TASSER server output for FHA-2 structure predictions are available at https://doi.org/10.17632/hrbmtfv754.1. CdiA sequences were aligned using Clustal Omega. FHA-1 sequences are in blue bold-face. CdiA STECO31 and CdiA EC93 RBD sequences are shown in salmon and pink, respectively. The YP domain is shown in black bold-face for CdiA STECO31 and CdiA EC93 , beginning with the YPLP peptide motif and extending to the periplasmic FHA-1 repeats (pFR). Cys-substituted positions (Ser1550, Ser1693, Gly1726 and Ala1807) in CdiA STECO31 are underlined and highlighted in yellow. CdiA sequences are from Pectobacterium carotovorum F152 (NCBI accession: PPE64673.1), Pectobacterium parmentieri WPP163 (ACX88282.1), Pectobacterium maceratum PB70 (POY59994.1), Brenneria goodwinii RBB141 (WP_095834043.1), Cedecea neteri NBRC 105707 (WP_061277518.1), Enterobacter cloacae MGH 54 (WP_084832630.1), Shigella flexneri 1235-66 (EIQ74285.1), Pantoea sp. OV426 (SFN23123.1), Dickeya chrysanthemi EC16 (AAN38708.1), Escherichia coli STEC_O31 (WP_001385946.1), Escherichia coli EC93 (AAZ57198.1), Serratia proteamaculans 568 (WP_012147097.1), and Yersinia mollaretii ATCC 43969 (WP_004876812.1). Figure S4 . CdiA STECO31 Amino Acid Residue Frequency, Related to Figure 2 Amino acid residues were counted within a sliding 40-residue window along the length of CdiA STECO31 . Domains are color-coded: TPS transport (green), FHA-1 (blue), RBD (maroon), FHA-2 (orange), and CdiA-CT (purple). The PT domain corresponds to the region between the dotted line and the CdiA-CT. 
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